NCT06522945View on ClinicalTrials.gov

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
Multi-resistant Gram-negative Bacteria Cause Infection
Interventions
DRUG

TQD3524

Polymyxin antibiotics

DRUG

TQD3524

Polymyxin antibiotics

DRUG

TQD3524

Polymyxin antibiotics

DRUG

TQD3524

Polymyxin antibiotics

DRUG

TQD3524

Polymyxin antibiotics

DRUG

TQD3524

Polymyxin antibiotics

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY